Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
about
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farRecent developments in receptor tyrosine kinases targeted anticancer therapyTen things you should know about protein kinases: IUPHAR Review 14A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Molecular pathways and therapeutic targets in lung cancerA road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.Representing and extracting lung cancer study metadata: study objective and study design.Ectokinases as novel cancer markers and drug targets in cancer therapy.Sex disparities in the association of lung adenocarcinoma with colorectal cancer.Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy.Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports.Nanoparticle-based targeted gene therapy for lung cancer.Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancerToxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer.Role of afatinib in the treatment of advanced lung squamous cell carcinoma.Impact of the structures of macrocyclic Michael acceptors on covalent proteasome inhibition.YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas.Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
P2860
Q26745776-2320C173-B630-4D9F-BFB3-9D2E2CA20602Q26751331-C98F1598-3FE1-48DE-8339-546E5AE501A3Q26849417-A4C166D8-DA1A-4F08-B43C-F564CAF6291AQ33605906-D3F9C771-A980-4CB3-A7D2-D416CA7EF314Q33688872-91FA0071-3F5D-49ED-9AED-2FC598F2669FQ34067085-D41D0ECB-88E3-4C8B-B6D2-E1E8B8FB6FEFQ35080328-1E48F149-4BFA-405F-9E9B-67E0228A2FFFQ35091362-D343E63E-69C2-432C-A419-82F1B362AFC9Q35236798-4D81C413-5B1C-4DF1-AD9F-9361FCEE0286Q37347517-FEA7AB45-0F36-4625-8F22-BA8CC1FBA35FQ37566833-2FD0353B-11C5-4DE5-AB4A-5F76E687B862Q37582259-E9AA65E2-3760-4B17-9A3D-8F0CB2039E45Q38854207-1BE5DD6C-8680-4A4F-8648-41DBE96E0D9CQ39118597-844B2D44-0EB6-43E7-A595-0197A7559903Q42178081-9845B9D5-5101-4C04-9605-4407A0895F64Q47093485-6A3F4EED-6F55-4AAD-A559-8D554AC4E836Q47106457-A6FB9C94-F88B-4F04-AF85-A75DB9490686Q47139623-553FD1E3-8A23-41B0-AF9D-7C24020D5DAEQ48267724-9DACF298-BE60-4A17-B01A-6DBEE6E8FBA6Q57177486-83D997FD-9316-4C4C-80D2-665EE087AB39
P2860
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@ast
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@en
type
label
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@ast
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@en
prefLabel
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@ast
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@en
P2093
P2860
P356
P1476
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
@en
P2093
Jacqueline Ziehr
Mark Agulnik
Melissa Johnson
Valerie Nelson
P2860
P304
P356
10.2147/OTT.S23165
P407
P577
2013-03-05T00:00:00Z